Professor Constantin Coussios is the Director of the Oxford Institute of Biomedical Engineering. He received his BA, MEng and PhD in Engineering from the University of Cambridge and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, with special responsibility for drug delivery and therapeutic devices. He founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), a research group of 4 faculty and some 45 researchers working on a wide array of therapeutic applications. Prof. Coussios received the UK’s Institute of Acoustics’ Young Person’s Award for Innovation in Acoustical Engineering in 2007, was elected as Secretary-General of the International Society for Therapeutic Ultrasound between 2006-2010 and was honoured with the Society’s Fred Lizzi award in 2012. He was elected as the youngest ever Fellow of the Acoustical Society of America in 2009, and received the Society’s Bruce Lindsay award in 2012. In 2008, he was one of two academic founders of the Oxford University spin-out OrganOx Ltd., which has developed a novel normothermic perfusion device for improved liver and kidney preservation prior to transplantation through to first-in-man trials, first sales, randomized trials (Nature 2018) and NICE approval. In 2014, he co-founded OxSonics Ltd, which is commercializing cavitation-enhanced oncological drug delivery, and in 2016 he co-founded OrthoSon Ltd, which is developing minimally invasive image-guided replacement of the intervertebral disc. In 2017, he received the Silver Medal of the UK’s Royal Academy of Engineering for his contributions to organ preservation and ultrasound-enhanced drug delivery. In 2019, he was elected a Fellow of the Royal Academy of Engineering.